Caplin Point Laboratories Future Growth
Future criteria checks 2/6
Caplin Point Laboratories is forecast to grow earnings and revenue by 13.6% and 13.2% per annum respectively. EPS is expected to grow by 13.6% per annum. Return on equity is forecast to be 18.6% in 3 years.
Key information
13.6%
Earnings growth rate
13.6%
EPS growth rate
| Pharmaceuticals earnings growth | 17.5% |
| Revenue growth rate | 13.2% |
| Future return on equity | 18.6% |
| Analyst coverage | Low |
| Last updated | 11 Nov 2024 |
Recent future growth updates
₹2,142 - That's What Analysts Think Caplin Point Laboratories Limited (NSE:CAPLIPOINT) Is Worth After These Results
Nov 10
Earnings Update: Here's Why Analysts Just Lifted Their Caplin Point Laboratories Limited (NSE:CAPLIPOINT) Price Target To ₹1,764
Aug 11Recent updates
Investor Optimism Abounds Caplin Point Laboratories Limited (NSE:CAPLIPOINT) But Growth Is Lacking
Dec 01₹2,142 - That's What Analysts Think Caplin Point Laboratories Limited (NSE:CAPLIPOINT) Is Worth After These Results
Nov 10With EPS Growth And More, Caplin Point Laboratories (NSE:CAPLIPOINT) Makes An Interesting Case
Oct 31Caplin Point Laboratories (NSE:CAPLIPOINT) Is Due To Pay A Dividend Of ₹2.50
Sep 12Earnings Update: Here's Why Analysts Just Lifted Their Caplin Point Laboratories Limited (NSE:CAPLIPOINT) Price Target To ₹1,764
Aug 11Caplin Point Laboratories (NSE:CAPLIPOINT) Is Paying Out A Dividend Of ₹2.50
Aug 10Investors Aren't Buying Caplin Point Laboratories Limited's (NSE:CAPLIPOINT) Earnings
Jul 12Caplin Point Laboratories (NSE:CAPLIPOINT) Strong Profits May Be Masking Some Underlying Issues
May 24Does Caplin Point Laboratories (NSE:CAPLIPOINT) Deserve A Spot On Your Watchlist?
May 04Caplin Point Laboratories Limited's (NSE:CAPLIPOINT) Low P/E No Reason For Excitement
Mar 07With EPS Growth And More, Caplin Point Laboratories (NSE:CAPLIPOINT) Makes An Interesting Case
Oct 24Why We Think The CEO Of Caplin Point Laboratories Limited (NSE:CAPLIPOINT) May Soon See A Pay Rise
Sep 15Caplin Point Laboratories (NSE:CAPLIPOINT) Will Pay A Larger Dividend Than Last Year At ₹2.50
Aug 11We Discuss Whether Caplin Point Laboratories Limited's (NSE:CAPLIPOINT) CEO Is Due For A Pay Rise
Sep 23Caplin Point Laboratories' (NSE:CAPLIPOINT) Shareholders Will Receive A Bigger Dividend Than Last Year
Sep 11Is Now The Time To Put Caplin Point Laboratories (NSE:CAPLIPOINT) On Your Watchlist?
Jul 22Caplin Point Laboratories (NSE:CAPLIPOINT) Is Increasing Its Dividend To ₹2.00
May 15A Look At The Intrinsic Value Of Caplin Point Laboratories Limited (NSE:CAPLIPOINT)
Jan 21Should You Be Adding Caplin Point Laboratories (NSE:CAPLIPOINT) To Your Watchlist Today?
Oct 20Caplin Point Laboratories (NSE:CAPLIPOINT) Is Increasing Its Dividend To ₹1.50
Sep 17Caplin Point Laboratories (NSE:CAPLIPOINT) Will Pay A Larger Dividend Than Last Year At ₹1.50
Sep 03Caplin Point Laboratories Limited's (NSE:CAPLIPOINT) Intrinsic Value Is Potentially 28% Above Its Share Price
Aug 27Is Caplin Point Laboratories (NSE:CAPLIPOINT) A Risky Investment?
Jun 12Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 3/31/2027 | 25,604 | 7,061 | 5,040 | 5,119 | 1 |
| 3/31/2026 | 22,369 | 5,806 | 4,138 | 5,220 | 3 |
| 3/31/2025 | 19,665 | 5,069 | 3,174 | 4,027 | 3 |
| 9/30/2024 | 18,328 | 4,936 | 2,310 | 3,748 | N/A |
| 6/30/2024 | 17,577 | 4,776 | N/A | N/A | N/A |
| 3/31/2024 | 16,961 | 4,571 | 1,726 | 3,184 | N/A |
| 12/31/2023 | 16,318 | 4,376 | N/A | N/A | N/A |
| 9/30/2023 | 15,683 | 4,179 | 399 | 2,593 | N/A |
| 6/30/2023 | 15,157 | 3,947 | N/A | N/A | N/A |
| 3/31/2023 | 14,683 | 3,763 | 779 | 2,714 | N/A |
| 12/31/2022 | 14,182 | 3,532 | N/A | N/A | N/A |
| 9/30/2022 | 13,724 | 3,307 | 2,305 | 3,467 | N/A |
| 6/30/2022 | 13,153 | 3,140 | N/A | N/A | N/A |
| 3/31/2022 | 12,710 | 2,998 | 2,456 | 3,367 | N/A |
| 12/31/2021 | 12,099 | 2,872 | N/A | N/A | N/A |
| 9/30/2021 | 11,581 | 2,767 | 1,288 | 2,044 | N/A |
| 6/30/2021 | 11,217 | 2,586 | N/A | N/A | N/A |
| 3/31/2021 | 10,624 | 2,423 | 1,953 | 2,686 | N/A |
| 12/31/2020 | 9,986 | 2,248 | N/A | N/A | N/A |
| 9/30/2020 | 9,524 | 2,189 | 1,650 | 1,877 | N/A |
| 6/30/2020 | 9,107 | 2,193 | N/A | N/A | N/A |
| 3/31/2020 | 8,640 | 2,150 | -321 | 447 | N/A |
| 12/31/2019 | 8,356 | 2,159 | N/A | N/A | N/A |
| 9/30/2019 | 7,664 | 2,032 | -331 | 830 | N/A |
| 6/30/2019 | 6,948 | 1,894 | N/A | N/A | N/A |
| 3/31/2019 | 6,490 | 1,766 | 182 | 834 | N/A |
| 12/31/2018 | 6,048 | 1,621 | N/A | N/A | N/A |
| 9/30/2018 | 5,874 | 1,538 | N/A | N/A | N/A |
| 6/30/2018 | 5,628 | 1,459 | N/A | N/A | N/A |
| 3/31/2018 | 5,399 | 1,448 | N/A | 665 | N/A |
| 12/31/2017 | 5,145 | 1,430 | N/A | N/A | N/A |
| 9/30/2017 | 4,757 | 1,297 | N/A | N/A | N/A |
| 6/30/2017 | 4,401 | 1,165 | N/A | N/A | N/A |
| 3/31/2017 | 4,016 | 956 | N/A | 676 | N/A |
| 12/31/2016 | 3,655 | 783 | N/A | N/A | N/A |
| 9/30/2016 | 3,420 | 703 | N/A | N/A | N/A |
| 6/30/2016 | 3,238 | 619 | N/A | N/A | N/A |
| 3/31/2016 | 3,088 | 584 | N/A | 565 | N/A |
| 12/31/2015 | 2,906 | 535 | N/A | N/A | N/A |
| 9/30/2015 | 2,722 | 465 | N/A | N/A | N/A |
| 6/30/2015 | 2,518 | 410 | N/A | 499 | N/A |
| 3/31/2015 | 2,296 | 353 | N/A | N/A | N/A |
| 12/31/2014 | 2,074 | 318 | N/A | N/A | N/A |
| 9/30/2014 | 1,893 | 305 | N/A | N/A | N/A |
| 6/30/2014 | 1,731 | 258 | N/A | 598 | N/A |
| 3/31/2014 | 1,643 | 204 | N/A | N/A | N/A |
| 12/31/2013 | 1,517 | 167 | N/A | N/A | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: CAPLIPOINT's forecast earnings growth (13.6% per year) is above the savings rate (6.7%).
Earnings vs Market: CAPLIPOINT's earnings (13.6% per year) are forecast to grow slower than the Indian market (18.1% per year).
High Growth Earnings: CAPLIPOINT's earnings are forecast to grow, but not significantly.
Revenue vs Market: CAPLIPOINT's revenue (13.2% per year) is forecast to grow faster than the Indian market (10.5% per year).
High Growth Revenue: CAPLIPOINT's revenue (13.2% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: CAPLIPOINT's Return on Equity is forecast to be low in 3 years time (18.6%).
Discover growth companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/30 23:18 |
| End of Day Share Price | 2024/12/30 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2024/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Caplin Point Laboratories Limited is covered by 3 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Rohit Bhat | Batlivala & Karani Securities India Pvt. Ltd. |
| Kameswari V. S. Chavali | FirstCall Research |
| Siddhant Khandekar | ICICIdirect.com |